The primary focus for targeted cancer agents has typically been to counteract the oncogenic signaling that results from genetic defects. A new strategy is emerging that actually seeks to exploit the oncogenic features of tumor cells rather than overcome them.
No takes yet. Share an insight, caveat, or question.
Jane De Lartigue (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: